109 related articles for article (PubMed ID: 23185750)
1. [Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer].
Chen JX; Shen XH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Sep; 32(9):1161-5. PubMed ID: 23185750
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant function of guilu erxian glue cataplasm in treating carcinoma of the large intestine patients with myelosuppression after chemotherapy: a clinical observation].
Wang J; Wei DN; Zhang WP; Ran R; Xu K; Gao JW; Lin SY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Aug; 34(8):947-51. PubMed ID: 25223178
[TBL] [Abstract][Full Text] [Related]
3. Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma.
Wang T; Nan H; Zhang C; Wang Y; Zhang X; Li Y;
J Cancer Res Ther; 2014 Aug; 10 Suppl 1():52-5. PubMed ID: 25207892
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C; Munemoto Y; Mishima H; Nagata N; Oshiro M; Kataoka M; Sakamoto J; Aoyama T; Morita S; Kono T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):97-103. PubMed ID: 25983022
[TBL] [Abstract][Full Text] [Related]
5. [Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy].
Xiao H; Yang J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Feb; 31(2):164-7. PubMed ID: 21425566
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
9. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Chemotherapy Related Leukocytopenia by Oral Administration of Multiple Leucogenic Drugs Combined with G-CSF: an Experimental Study].
Zhang XP; Zhang X; Yang HJ; Zou DH; He XM; Yu XF; Li YF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jul; 35(7):860-5. PubMed ID: 26380451
[TBL] [Abstract][Full Text] [Related]
11. A clinical study on safety and efficacy of Aidi injection combined with chemotherapy.
Xu HX; Huang XE; Li Y; Li CG; Tang JH
Asian Pac J Cancer Prev; 2011; 12(9):2233-6. PubMed ID: 22296362
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Marshall JL; Richmond E; DeLap RJ
Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
[TBL] [Abstract][Full Text] [Related]
13. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
[TBL] [Abstract][Full Text] [Related]
15. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
16. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
[TBL] [Abstract][Full Text] [Related]
17. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
18. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
[TBL] [Abstract][Full Text] [Related]
19. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
20. [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Cai X; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):39-43. PubMed ID: 22490854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]